UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
19.10
+1.07 (5.93%)
At close: Apr 8, 2026, 4:00 PM EDT
18.72
-0.38 (-1.99%)
After-hours: Apr 8, 2026, 7:31 PM EDT
UroGen Pharma Revenue
In the year 2025, UroGen Pharma had annual revenue of $109.79M with 21.45% growth. UroGen Pharma had revenue of $37.84M in the quarter ending December 31, 2025, with 54.03% growth.
Revenue (ttm)
$109.79M
Revenue Growth
+21.45%
P/S Ratio
8.47
Revenue / Employee
$377,278
Employees
291
Market Cap
929.83M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 109.79M | 19.39M | 21.45% |
| Dec 31, 2024 | 90.40M | 7.69M | 9.29% |
| Dec 31, 2023 | 82.71M | 18.36M | 28.52% |
| Dec 31, 2022 | 64.36M | 16.32M | 33.96% |
| Dec 31, 2021 | 48.04M | 36.24M | 307.17% |
| Dec 31, 2020 | 11.80M | 11.78M | 65,450.00% |
| Dec 31, 2019 | 18.00K | -1.11M | -98.40% |
| Dec 31, 2018 | 1.13M | -7.03M | -86.17% |
| Dec 31, 2017 | 8.16M | -9.37M | -53.46% |
| Dec 31, 2016 | 17.53M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xencor | 125.58M |
| CytomX Therapeutics | 76.20M |
| Janux Therapeutics | 10.00M |
| Aktis Oncology | 6.50M |
| Inhibrx Biosciences | 1.30M |
URGN News
- 15 hours ago - UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer - GlobeNewsWire
- 9 days ago - Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI - GlobeNewsWire
- 4 weeks ago - UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors - GlobeNewsWire
- 5 weeks ago - ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC - GlobeNewsWire
- 6 weeks ago - UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 6 weeks ago - UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026 - GlobeNewsWire